Drugs Made in America Acquisition CORP Schedule 13G passive stakes

Several First Trust entities have jointly filed an amended Schedule 13G, reporting their beneficial ownership of Drugs Made In America Acquisition Corp. Class A Ordinary Shares.

Glazer Capital, LLC and Paul J. Glazer have reported beneficial ownership of 4.12% of Drugs Made in America Acquisition Corp.'s ordinary shares.

Mizuho Financial Group, Inc. has disclosed beneficial ownership of 2,058,605 common shares, representing 8.5% of the class, in Drugs Made In America Acquisition Corp.

Feis Equities LLC and Lawrence M. Feis have filed a Schedule 13G reporting a 5.08% beneficial ownership stake in Drugs Made In America Acquisition Corp.

Mizuho Financial Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.0% of Drugs Made In America Acquisition Corp. common shares.

Hudson Bay Capital Management LP and Sander Gerber report a 4.62% beneficial ownership stake in Drugs Made In America Acquisition Corp. ordinary shares.

Karpus Management, Inc. has disclosed an 8.19% beneficial ownership stake in Drugs Made In America Acquisition Corp., holding over 2.7 million common shares.

Multiple First Trust entities, including First Trust Merger Arbitrage Fund and First Trust Capital Management L.P., have disclosed passive beneficial ownership exceeding 5% in Drugs Made In America Acquisition Corp.'s Class A Ordinary Shares.

Glazer Capital, LLC and its managing member, Paul J. Glazer, have disclosed a beneficial ownership of 5.44% in Drugs Made in America Acquisition Corp.'s Ordinary Shares.

Polar Asset Management Partners Inc. has reported a 5.7% beneficial ownership stake in Drugs Made In America Acquisition Corp, holding 1.9 million ordinary shares.

Karpus Management, Inc. has reported a beneficial ownership of 6.93% in Drugs Made In America Acquisition Corp., holding over 2.3 million shares with sole voting and dispositive power.

Hudson Bay Capital Management LP and Sander Gerber have disclosed a beneficial ownership of 5.37% in Drugs Made In America Acquisition Corp., holding 1,800,000 ordinary shares.